vTv Therapeutics (VTVT) Change in Accured Expenses (2014 - 2026)
vTv Therapeutics (VTVT) reported Change in Accured Expenses of $264000.0 for Q1 2026, up 131.58% on a YoY basis from $114000.0 in Q1 2025, and up 925.0% sequentially from -$32000.0 in Q4 2025.
vTv Therapeutics (VTVT) Change in Accured Expenses (2014 - 2026) Analysis & Trends
vTv Therapeutics (VTVT) has 13 years of Change in Accured Expenses data on file, last reported at $264000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses rose 131.58% year-over-year to $264000.0; the trailing twelve-month figure through Mar 2026 stood at $931000.0 (up 120.51% YoY), and the FY2025 full-year result was -$169000.0, up 96.76% from the prior year.
- Change in Accured Expenses climbed to $264000.0 in Q1 2026, from -$32000.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $4.4 million in Q1 2022 to a low of -$3.0 million in Q3 2022.
- A 5-year average of -$136937.5 and a median of -$39500.0 in 2025 frame the typical range for Change in Accured Expenses.
- Peak annual rise in Change in Accured Expenses reached 477.66% in 2022, while the deepest fall reached 2143.41% in 2022.
- Tracing VTVT's Change in Accured Expenses over 5 years: stood at $1.4 million in 2022, then slumped by 53.49% to $659000.0 in 2023, then tumbled by 281.94% to -$1.2 million in 2024, then surged by 97.33% to -$32000.0 in 2025, then soared by 925.0% to $264000.0 in 2026.
- Business Quant data shows VTVT's Change in Accured Expenses at $264000.0 in Q1 2026, -$32000.0 in Q4 2025, and -$47000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -16.74 Mn |
| 10 | vTv Therapeutics | 19.21 Mn | 19.21 Mn | - | 264,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 264,000.00 |
| Mar 31, 2026 | 264,000.00 |
| Dec 31, 2025 | -32,000.00 |
| Dec 31, 2025 | -32,000.00 |
| Sep 30, 2025 | -47,000.00 |
| Sep 30, 2025 | -47,000.00 |
| Jun 30, 2025 | 746,000.00 |
| Jun 30, 2025 | 746,000.00 |
| Mar 31, 2025 | -836,000.00 |
| Mar 31, 2025 | -836,000.00 |
| Dec 31, 2024 | -1.20 Mn |
| Dec 31, 2024 | -1.20 Mn |
| Sep 30, 2024 | -565,000.00 |
| Sep 30, 2024 | -565,000.00 |
| Jun 30, 2024 | -1.94 Mn |
| Jun 30, 2024 | -1.94 Mn |
| Mar 31, 2024 | -1.51 Mn |
| Mar 31, 2024 | -1.51 Mn |
| Dec 31, 2023 | 659,000.00 |
| Dec 31, 2023 | 659,000.00 |